Nevakar, headquartered in Bridgewater, New Jersey, is a specialty pharmaceutical company focused on developing innovative ophthalmic and injectable products.
The company’s goal is to create value for the healthcare system by offering products that are accessible and lead to better outcomes for patients.
These drug repositioning efforts are focused on:
- Studying new therapeutic indication of existing molecules
- Developing novel or superior formulations
- Designing improved, safer and more functional packaging
- Implementing effective regulatory and clinical strategies that support new uses or indications
These new products with proprietary enhancements are filed with the FDA, primarily under the 505(b)(2) regulatory pathway.
Nevakar's business model is supported by state-of-the-art R&D infrastructure and a highly experienced management and leadership team.
For more information visit: http://www.Nevakar.com